<DOC>
	<DOCNO>NCT00139789</DOCNO>
	<brief_summary>This multicenter , open-label , randomize , crossover trial subject MS already take stable dose baclofen ( 80 mg/day ) spasticity . The trial design ass subject preference Kemstro conventional baclofen . At Visit 1 , subject screen , qualify , randomly assign one two follow treatment sequence : Kemstro/conventional baclofen conventional baclofen/Kemstro .</brief_summary>
	<brief_title>A Multicenter , Open-label Randomized Crossover Trial Assess Subject Preference Kemstroâ„¢ Compared Conventional Baclofen Tablets Subjects With Stable Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>stable dose baclofen stable dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>